Systematic review and meta-analysis of liver resection for metastatic melanoma

British Journal of Surgery

Volumn 100, Issue 9, 2013, Pages 1138-1147

  Aubin, J M ^a   Rekman, J ^a   Vandenbroucke Menu, F ^b   Lapointe, R ^b   Fairfull Smith, R J ^a   Mimeault, R ^a   Balaa, F K ^a   Martel, G ^a,b  

^a UNIVERSITY OF OTTAWA   (Canada)

^b UNIVERSITY OF MONTREAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; FEMALE; HUMAN; LIVER RESECTION; LIVER TUMOR; MALE; MELANOMA; META ANALYSIS; METASTASIS; METHODOLOGY; MIDDLE AGED; REVIEW; SKIN TUMOR; TREATMENT OUTCOME;

ADULT; AGED; FEMALE; HEPATECTOMY; HUMANS; LIVER NEOPLASMS; MALE; MELANOMA; MIDDLE AGED; SKIN NEOPLASMS; TREATMENT OUTCOME;

EID: 84880135197     PISSN: 00071323     EISSN: 13652168     Source Type: Journal    
DOI: 10.1002/bjs.9189     Document Type: Review

References (55)

1. Jemal A, Siegel R, Xu J, Ward E,. Cancer statistics, 2010. CA Cancer J Clin 2010; 60: 277-300.
2. Balch CM, Soong SJ, Gershenwald JE, Thompson JF, Reintgen DS, Cascinelli N, et al,. Prognostic factors analysis of 17 600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system. J Clin Oncol 2001; 19: 3622-3634.
3. Algazi AP, Soon CW, Daud AI,. Treatment of cutaneous melanoma: current approaches and future prospects. Cancer Manag Res 2010; 2: 197-211.
4. Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, et al,. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010; 363: 711-723.
5. Robert C, Thomas L, Bondarenko I, O'Day S, Weber J, Garbe C, et al,. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 2011; 364: 2517-2526.
6. Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J, et al,.; BRIM-3 Study Group. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011; 364: 2507-2516.
7. Flaherty KT, Robert C, Hersey P, Nathan P, Garbe C, Milhem M, et al,.; METRIC Study Group. Improved survival with MEK inhibition in BRAF-mutated melanoma. N Engl J Med 2012; 367: 107-114.
8. Carvajal RD, Antonescu CR, Wolchok JD, Chapman PB, Roman RA, Teitcher J, et al,. KIT as a therapeutic target in metastatic melanoma. JAMA 2011; 305: 2327-2334.
9. Zani S, Clary BM,. A role for hepatic metastasectomy in stage IV melanoma and breast cancer: reestablishing the surgical modality. Oncology 2011; 25: 1158-1164.
10. Leiter U, Meier F, Schittek B, Garbe C,. The natural course of cutaneous melanoma. J Surg Oncol 2004; 86: 172-178.
11. Gragoudas ES, Egan KM, Seddon JM, Glynn RJ, Walsh SWM, Finn SM, et al,. Survival of patients with metastases from uveal melanoma. Ophthalmology 1991; 98: 383-389.
12. Eskelin S, PyrhÓnen S, Summanen P, Prause JU, Klvelä T,. Screening for metastatic malignant melanoma of the uvea revisited. Cancer 1999; 85: 1151-1159.
13. Dithmar S, Diaz CE, Grossniklaus HE,. Intraocular melanoma spread to regional lymph nodes: report of two cases. Retina 2000; 20: 76-79.
14. Crowley NJ, Seigler HF,. Late recurrence of malignant melanoma. Analysis of 168 patients. Ann Surg 1990; 212: 173-177.
15. Lehmann K, Rickenbacher A, Weber A, Pestalozzi BC, Clavien PA,. Chemotherapy before liver resection of colorectal metastases: friend or foe? Ann Surg 2012; 255: 237-247.
16. Higgins JPT, Green S, (eds). Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. http://www.cochrane-handbook.org [accessed 14 September 2012].
17. Booth A, Clarke M, Dooley G, Ghersi D, Moher D, Petticrew M, et al,. The nuts and bolts of PROSPERO: an international prospective register of systematic reviews. Syst Rev 2012; 1: 2.
18. Slim K, Nini E, Forestier D, Kwiatkowski F, Panis Y, Chipponi J,. Methodological index for non-randomized studies (MINORS): development and validation of a new instrument. ANZ J Surg 2003; 73: 712-716.
19. Abraham NS, Byrne CJ, Young JM, Solomon MJ,. Meta-analysis of well-designed nonrandomized comparative studies of surgical procedures is as good as randomized controlled trials. J Clin Epidemiol 2010; 63: 238-245.
20. Williamson PR, Smith CT, Hutton JL, Marson AG,. Aggregate data meta-analysis with time-to-event outcomes. Stat Med 2002; 21: 3337-3351.
21. Parmar MKB, Torri V, Stewart L,. Extracting summary statistics to perform meta-analysis of the published literature for survival endpoints. Stat Med 1998; 17: 2815-2834.
22. Tierney JF, Stewart LA, Ghersi D, Burdett S, Sydes MR,. Practical methods for incorporating summary time-to-event data into meta-analysis. Trials 2007; 8: 16.
23. Sydes M, Tierney J,. HR Calculation Spreadsheet. MRC Clinical Trials Unit: London. http://www.biomedcentral.com/content/supplementary/1745-6215-8-16- S1.xls%5D [accessed 1 April 2012].
24. Adam R, Chiche L, Aloia T, Elias D, Salmon R, Rivoire M, et al,. Hepatic resection for noncolorectal nonendocrine liver metastases: analysis of 1452 patients and development of a prognostic model. Ann Surg 2006; 244: 524-535.
25. Caralt M, Martí J, Cortés J, Fondevilla C, Bilbao I, Fuster J, et al,. Outcome of patients following hepatic resection for metastatic cutaneous and ocular melanoma. J Hepatobiliary Pancreat Sci 2011; 18: 268-275.
26. Chua T, Saxena A, Morris DL,. Surgical metastasectomy in AJCC stage IV M1c melanoma with gastrointestinal and liver metastases. Ann Acad Med Singapore 2010; 39: 634-639.
27. Elias D, de Albuquerque AC, Eggenspieler P, Plaud B, Ducreux M, Spielman M, et al,. Resection of liver metastases from a noncolorectal primary: indications and results based on 147 monocentric patients. J Am Coll Surg 1998; 187: 487-493.
28. Frenkel S, Nir I, Hendler K, Lotem M, Eid A, Jurim O, et al,. Long-term survival of uveal melanoma patients after surgery for liver metastases. Br J Ophthalmol 2009; 93: 1042-1046.
29. Groeschl RT, Nachmany I, Steel JL, Reddy SK, Glazer ES, de Jong MC, et al,. Hepatectomy for noncolorectal non-neuroendocrine metastatic cancer: a multi-institutional analysis. J Am Coll Surg 2012; 214: 769-777.
30. Herman P, Machado MAC, Montagnini AL, D'Albuquerque LAC, Saad WA, Machado MCC,. Selected patients with metastatic melanoma may benefit from liver resection. World J Surg 2007; 31: 171-174.
31. Lehner F, Ramackers W, Bektas H, Becker T, Klempnauer J. [Liver resection for non-colorectal, non-neuroendocrine liver metastases-is hepatic resection justified as part of the oncosurgical treatment?] Zentralbl Chir 2009; 134: 430-436.
32. Mariani P, Piperno-Neumann S, Servois V, Berry MG, Dorval T, Plancher C, et al,. Surgical management of liver metastases from uveal melanoma: 16 years' experience at the Institut Curie. Eur J Surg Oncol 2009; 35: 1192-1197.
33. Marshall E, Romaniuk C, Ghaneh P, Wong H, McKay M, Chopra M, et al,. MRI in the detection of hepatic metastases from high-risk uveal melanoma: a prospective study in 188 patients. Br J Ophthalmol 2013; 97: 159-163.
34. Pawlik TM, Zorzi D, Abdalla EK, Clary BM, Gershenwald JE, Ross MI, et al,. Hepatic resection for metastatic melanoma: distinct patterns of recurrence and prognosis for ocular versus cutaneous disease. Ann Surg Oncol 2006; 13: 712-720.
35. Pilati PL, Mammano E, Tessari E, Briarava M, Mattara G, Rossi CR, et al,. Multimodal treatments for liver metastases from melanoma: experience of a single institution. Ann Surg Oncol 2010; 17 (Suppl 1): S1-S139.
36. Piperno-Neumann S, Chaaba H, Plancher C, Mariani P, Couturier J, Sastre-Garau X, et al,. Retrospective analysis of 470 metastatic uveal melanoma (MUM) patients managed at Institut Curie between 2000 and 2008. Ann Onco l 2010; 21 (Suppl 8): viii401.
37. Reddy SK, Barbas AS, Marroquin CE, Morse MA, Kuo PC, Clary BM,. Resection of noncolorectal nonneuroendocrine liver metastases: a comparative analysis. J Am Coll Surg 2006; 204: 372-382.
38. de Ridder J, van Walsum M, Verhoef C, Nagtegaal ID, de Wilt J; Dutch Liver Working Group. Hepatic resection for metastatic melanoma in the Netherlands-survival and prognostic factors. Eur J Surg Oncol 2012; 38: 773-774.
39. Ripley RT, Davis JL, Klapper JA, Mathur A, Kammula U, Royal RE, et al,. Liver resection for metastatic melanoma with postoperative tumor-infiltrating lymphocyte therapy. Ann Surg Oncol 2010; 17: 163-170.
40. Rivoire M, Kodjikian L, Baldo S, Kaemerlen P, Négrier S, Grange J-D,. Treatment of liver metastases from uveal melanoma. Ann Surg Oncol 2005; 12: 422-428.
41. Rose DM, Essner R, Hughes MD, Tang PC, Bilchik A, Wanek LA, et al,. Surgical resection for metastatic melanoma to the liver. Arch Surg 2001; 136: 950-955.
42. Ryu SW, Saw R, Scolyer R, Gallagher J, Crawford M, Joseph D, et al,. Surgical management of liver metastasis from metastatic melanoma. HPB 2012; 14: 159-160.
43. Salmon RJ, Levy C, Plancher C, Dorval T, Desjardins L, Leyvraz S, et al,. Treatment of liver metastases from uveal melanoma by combined surgery-chemotherapy. Eur J Surg Oncol 1998; 24: 127-130.
44. Wood TF, DiFronzo LA, Rose MA, Haigh PI, Stern SL, Wanek L, et al,. Does complete resection of melanoma metastatic to solid intra-abdominal organs improve survival? Ann Surg 2001; 8: 658-662.
45. Malassagne B, Goere D, Cherqui D, Fagniez P-L,. Traitement chirurgical des metastases hépatiques non colorectales et non endocrines. Gastroenterol Clin Biol 2000; 24: 1177-1185.
46. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Melanoma. Version I.2013. http://www.nccn.org [accessed 2 October 2012].
47. Barth A, Wanek LA, Morton DL,. Prognostic factors in 1521 melanoma patients with distant metastases. J Am Coll Surg 1995; 181: 193-201.
48. Spiguel LRP, Khan SA,. Hepatic metastasectomy for breast cancer and melanoma: trends in highly selected patients. Oncology 2011; 25: 1173-1175.
49. Fong Y, Fortner J, Sun RL, Brennan MF, Blumgart LH,. Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. Ann Surg 1999; 230: 309-318.
50. Chua TC, Saxena A, Liauw W, Chu F, Morris DL,. Hepatic resection for metastatic breast cancer: a systematic review. Eur J Cancer 2011; 47: 2282-2290.
51. de Haas RJ, Wicherts DA, Flores E, Azoulay D, Castaing D, Adam R,. R1 resection by necessity for colorectal liver metastases: is it still a contraindication to surgery? Ann Surg 2008; 248: 626-637.
52. Crowley NJ, Seigler HF,. Late recurrence of malignant melanoma: analysis of 168 patients. Ann Surg 1990; 212: 173-177.
53. Rietschel P, Panageas KS, Hanlon C, Patel A, Abramson DH, Chapman PB,. Variates of survival in metastatic uveal melanoma. J Clin Oncol 2005; 23: 8076-8080.
54. Allen PJ, Coit DG,. The surgical management of metastatic melanoma. Ann Surg Oncol 2002; 9: 762-770.
55. Kornprat P, Jarnagin WR, Gonen M, DeMatteo RP, Fong Y, Blumgart LH, et al,. Outcome after hepatectomy for multiple (four or more) colorectal metastases in the era of effective chemotherapy. Ann Surg Oncol 2007; 14: 1151-1160.